Biotricity Inc. (Biotricity)announced today the official launch a new digital presence that illustrates more completely the depth of Biotricity technologies and solutions. The company has built a suite of solutions that combine connectivity, smart analytics, AI and cutting-edge cloud technologies. The solutions support individuals and patients from diagnostics to disease management depending on the solution utilized.
Biotricity Inc. (Biotricity) today reported that it achieved a record $14 million annualized revenue run rate in August, extending its growth by over eight percent from the previously announced $13 million run rate. In its Corporate Impact Report published last spring, Biotricity described both “better patient outcomes and substantial cost savings” for patients using its devices.
Biotricity Inc. (Biotricity) today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023. The company reported that the Q1-FY24 revenue grew by 46.9% YOY to $3.0 million, continuing to advance toward positive cashflow.
Biotricity Inc. (Biotricity) today announced its strengthened relationships with Amazon and Google. The Company is expanding its AI technology development in remote cardiac care, leveraging its proprietary AI technology to provide a suite of predictive monitoring tools to enhance new disease profiling, improve patient management, and revolutionize the healthcare industry for disease prevention.
Biotricity Inc. (Biotricity) today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on July 18, 2023 informing that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Consequently, Biotricity is now in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market.
Biotricity Inc. (Biotricity) today reported a strong start to its Fiscal Year 2024 ending March 31, 2024 and provided a preliminary estimate of its revenue for its first quarter of fiscal year 2024. For the first fiscal quarter ended June 30, 2023, the Company expects to report an approximate increase in revenue which represents growth of over 40% YOY from the corresponding prior year quarter and expects to achieve continued reduction in expenses.
Biotricity Inc. (Biotricity) today announced that it will effect a reverse stock split of its common stock. Biotricity expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on July 3, 2023. The reverse stock split was approved by the Board of Directors of the Company and is intended to increase the per share trading price of the Company’s common stock to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Biotricity Inc. (Biotricity) today reported that it reached a record $13 million annualized revenue run rate in April, further extending its growth by over eight percent from the $12 million run rate it announced for March 2023. In its Corporate Impact Report published earlier this month, Biotricity described both “better patient outcomes and substantial cost savings” for patients using its devices.
Biotricity Inc. (Biotricity) reported that it reached a record $12 million annualized revenue run rate in March 2023. Based on preliminary month-to-date results and internal projections, the Company remains excited regarding potential top line revenue growth in April and the current quarter (Q4FY23) as it maintains optimized investment in R&D, sales and marketing. The Company attributed its strengthening financials to the growing sales of its product line of remote cardiac monitors spanning consumers to cardiologists, the ramp up of its subscription-based recurring service revenues, and the early success of its recently expanded distribution strategy.
Biotricity Inc. (Biotricity) has released its first has released its first Corporate Impact Report– revealing that the company’s remote, clinical-grade diagnostic devices are inducing “better patient outcomes and substantial cost savings” across the nation. Presenting new data, the report highlights specific examples of Biotricity’s impact on “reforming the healthcare market by bridging the gap between effective remote diagnostics, remote patient monitoring and chronic care management.”
